Page 2 - Visual Acuity News Today

Joseph M. Coney, MD, FACS, emphasizes the vital role of community engagement in tackling difference in social determinants of health among patients with diabetes and highlights the significance of multilevel efforts to enhance community health outcomes.

1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Geographic atrophy is a severe form of age-related macular degeneration that can lead to irreversible vision loss. Currently, limited treatments exist. Avacincaptad pegol is a complement C5 inhibitor that

The PALADIN study reported the intravitreal fluocinolone acetonide implant reduced the frequency of anti-VEGF injections in patients with diabetic macular edema out to 3 years.

(NAPSI)—If any of the approximately 74 million schoolchildren in the U.S. is someone you care about, here’s something you may want to look into: According to the National Institutes of Health …

(NAPSI)—If any of the approximately 74 million schoolchildren in the U.S. is someone you care about, here’s something you may want to look into: According to the National Institutes of Health …

Sweden: A follow-up of a randomized controlled trial revealed that postnatal supplementation with enteral polyunsaturated fatty acids in extremely preterm children leads to better visual function by...

Phase 3 registration trials found the comparability of two biosimilars to reference aflibercept in terms of efficacy, safety, pharmacokinetics, and immunogenicity.

Recalled in 2022, a port delivery system for ranibizumab to treat wet AMD demonstrated that vision and retinal anatomy remained stable in patients who had the device for 5 years.

Older adults with vision problems may be more likely to develop dementia, a new study published in JAMA Ophthalmology found. Experts reveal the link between eye health and brain health.

Patients with a progressive form of Leber hereditary optic neuropathy (LHON) that causes rapid vision loss experienced improvement in their eyesight with an experimental gene therapy.